{"transactions":[{"id":3092437,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":148048,"kind":"person","name":"Christenson Johan","position":1,"cik":"0001488771","reported_name":"Christenson Johan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Preferred Exchangeable Shares","published_at":"2020-07-02T16:02:27.000Z","date":"2020-06-30","kind":"exercise","acquired":false,"shares":5712216,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Represents Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited are redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class B Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. The Class B Preferred Exchangeable Shares have no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Represents Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited are redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class B Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. The Class B Preferred Exchangeable Shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited are redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class B Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. The Class B Preferred Exchangeable Shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited are redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class B Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. The Class B Preferred Exchangeable Shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited are redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class B Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. The Class B Preferred Exchangeable Shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held directly by HealthCap VII, L.P. (\"HCLP\"). HealthCap VII GP SA (\"HCSA\") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":1069902},"source":{"system":"sec-edgar","filing":"0000899243-20-018257","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320018257/doc4.xml","form_type":"4"}},{"id":3092436,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":148048,"kind":"person","name":"Christenson Johan","position":1,"cik":"0001488771","reported_name":"Christenson Johan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Preferred Exchangeable Shares","published_at":"2020-07-02T16:02:27.000Z","date":"2020-06-30","kind":"exercise","acquired":false,"shares":13333333,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited are redeemable into Class A Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class A Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. The Class A Preferred Exchangeable Shares have no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited are redeemable into Class A Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class A Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. The Class A Preferred Exchangeable Shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited are redeemable into Class A Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class A Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. The Class A Preferred Exchangeable Shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited are redeemable into Class A Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class A Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. The Class A Preferred Exchangeable Shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited are redeemable into Class A Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class A Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. The Class A Preferred Exchangeable Shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held directly by HealthCap VII, L.P. (\"HCLP\"). HealthCap VII GP SA (\"HCSA\") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":2497345},"source":{"system":"sec-edgar","filing":"0000899243-20-018257","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320018257/doc4.xml","form_type":"4"}},{"id":3092435,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":148048,"kind":"person","name":"Christenson Johan","position":1,"cik":"0001488771","reported_name":"Christenson Johan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-07-02T16:02:27.000Z","date":"2020-06-30","kind":"purchase","acquired":true,"shares":240000,"price":17,"value":4080000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held directly by HealthCap VII, L.P. (\"HCLP\"). HealthCap VII GP SA (\"HCSA\") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein."}],"balance_after":3807247,"source":{"system":"sec-edgar","filing":"0000899243-20-018257","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320018257/doc4.xml","form_type":"4"}},{"id":3092434,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":148048,"kind":"person","name":"Christenson Johan","position":1,"cik":"0001488771","reported_name":"Christenson Johan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-07-02T16:02:27.000Z","date":"2020-06-30","kind":"exercise","acquired":true,"shares":1069902,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited are redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class B Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. The Class B Preferred Exchangeable Shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held directly by HealthCap VII, L.P. (\"HCLP\"). HealthCap VII GP SA (\"HCSA\") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein."}],"balance_after":3567247,"source":{"system":"sec-edgar","filing":"0000899243-20-018257","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320018257/doc4.xml","form_type":"4"}},{"id":3092433,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":148048,"kind":"person","name":"Christenson Johan","position":1,"cik":"0001488771","reported_name":"Christenson Johan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-07-02T16:02:27.000Z","date":"2020-06-30","kind":"exercise","acquired":true,"shares":2497345,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited are redeemable into Class A Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class A Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. The Class A Preferred Exchangeable Shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held directly by HealthCap VII, L.P. (\"HCLP\"). HealthCap VII GP SA (\"HCSA\") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein."}],"balance_after":2497345,"source":{"system":"sec-edgar","filing":"0000899243-20-018257","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320018257/doc4.xml","form_type":"4"}},{"id":3095174,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":148048,"kind":"person","name":"Christenson Johan","position":1,"cik":"0001488771","reported_name":"Christenson Johan","relationship":{"director":true}}],"security":"Stock Option (right to Buy)","published_at":"2020-07-01T18:01:06.000Z","date":"2020-06-30","kind":"grant","acquired":true,"shares":5600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on June 30, 2021 subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":5600,"derivative":{"exercise_price":38.78,"expiration_date":"2030-06-30","underlying":"Common Stock","underlying_shares":5600},"source":{"system":"sec-edgar","filing":"0000905148-20-000749","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488771/000090514820000749/form4.xml","form_type":"4"}},{"id":3096763,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":148048,"kind":"person","name":"Christenson Johan","position":1,"cik":"0001488771","reported_name":"Christenson Johan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-30T06:37:38.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option shall vest and become exercisable in 36 equal monthly installments commencing on July 18, 2020."}],"balance_after":30000,"derivative":{"exercise_price":17,"expiration_date":"2030-06-18","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-20-017874","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320017874/doc4.xml","form_type":"4"}},{"id":3096762,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":148048,"kind":"person","name":"Christenson Johan","position":1,"cik":"0001488771","reported_name":"Christenson Johan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Preferred Exchangeable Shares","published_at":"2020-06-30T06:37:38.000Z","date":"2020-06-02","kind":"purchase","acquired":true,"shares":2856108,"price":1.1514,"value":3288522.7512,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Represents Class B Preferred Exchangeable Shares of Fusion (Pharmaceuticals) Ireland Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited are redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited will be redeemed into Class B Preferred Shares on a one-for-one basis, which will subsequently convert on a one-for-5.339 basis into the number of Common Shares shown in column 7. The Class B Preferred Exchangeable Shares have no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Represents Class B Preferred Exchangeable Shares of Fusion (Pharmaceuticals) Ireland Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited are redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited will be redeemed into Class B Preferred Shares on a one-for-one basis, which will subsequently convert on a one-for-5.339 basis into the number of Common Shares shown in column 7. The Class B Preferred Exchangeable Shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents Class B Preferred Exchangeable Shares of Fusion (Pharmaceuticals) Ireland Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited are redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited will be redeemed into Class B Preferred Shares on a one-for-one basis, which will subsequently convert on a one-for-5.339 basis into the number of Common Shares shown in column 7. The Class B Preferred Exchangeable Shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents Class B Preferred Exchangeable Shares of Fusion (Pharmaceuticals) Ireland Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited are redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited will be redeemed into Class B Preferred Shares on a one-for-one basis, which will subsequently convert on a one-for-5.339 basis into the number of Common Shares shown in column 7. The Class B Preferred Exchangeable Shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held directly by HealthCap VII, L.P. (\"HCLP\"). HealthCap VII GP SA (\"HCSA\") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein."}],"balance_after":5712216,"derivative":{"underlying":"Common Shares","underlying_shares":534951},"source":{"system":"sec-edgar","filing":"0000899243-20-017874","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320017874/doc4.xml","form_type":"4"}},{"id":3096761,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":148048,"kind":"person","name":"Christenson Johan","position":1,"cik":"0001488771","reported_name":"Christenson Johan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to purchase Class B Preferred Exchangeable Shares","published_at":"2020-06-30T06:37:38.000Z","date":"2020-01-10","kind":"grant","acquired":true,"shares":576233,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents Warrants to Purchase Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited will become warrants to purchase Common Shares of the Issuer at an exercise price of $8.10 per share."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents Warrants to Purchase Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited will become warrants to purchase Common Shares of the Issuer at an exercise price of $8.10 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents Warrants to Purchase Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited will become warrants to purchase Common Shares of the Issuer at an exercise price of $8.10 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents Warrants to Purchase Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited will become warrants to purchase Common Shares of the Issuer at an exercise price of $8.10 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held directly by HealthCap VII, L.P. (\"HCLP\"). HealthCap VII GP SA (\"HCSA\") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein."}],"balance_after":576233,"derivative":{"exercise_price":1.1514,"exercise_date":"2020-01-10","expiration_date":"2022-01-10","underlying":"Common Shares","underlying_shares":107929},"source":{"system":"sec-edgar","filing":"0000899243-20-017874","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320017874/doc4.xml","form_type":"4"}},{"id":3396644,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":148048,"kind":"person","name":"Christenson Johan","position":1,"cik":"0001488771","reported_name":"Christenson Johan","relationship":{"director":true}}],"security":"Series C Convertible Preferred Stock","published_at":"2019-10-07T19:33:59.000Z","date":"2019-10-07","kind":"exercise","acquired":false,"shares":427496,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock (\"Shares\"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock (\"Shares\"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock (\"Shares\"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock (\"Shares\"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These Shares and Preferred Stock are held directly by HealthCap VII, L.P. (\"HCLP\"). HealthCap VII GP SA (\"HCSA\") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB.  The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These Shares and Preferred Stock are held directly by HealthCap VII, L.P. (\"HCLP\"). HealthCap VII GP SA (\"HCSA\") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB.  The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":427496},"source":{"system":"sec-edgar","filing":"0001140361-19-018087","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1488771/000114036119018087/form4.xml","form_type":"4"}},{"id":3396643,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":148048,"kind":"person","name":"Christenson Johan","position":1,"cik":"0001488771","reported_name":"Christenson Johan","relationship":{"director":true}}],"security":"Series B Convertible Preferred Stock","published_at":"2019-10-07T19:33:59.000Z","date":"2019-10-07","kind":"exercise","acquired":false,"shares":1661382,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock (\"Shares\"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock (\"Shares\"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock (\"Shares\"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock (\"Shares\"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These Shares and Preferred Stock are held directly by HealthCap VII, L.P. (\"HCLP\"). HealthCap VII GP SA (\"HCSA\") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB.  The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These Shares and Preferred Stock are held directly by HealthCap VII, L.P. (\"HCLP\"). HealthCap VII GP SA (\"HCSA\") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB.  The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1661382},"source":{"system":"sec-edgar","filing":"0001140361-19-018087","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1488771/000114036119018087/form4.xml","form_type":"4"}},{"id":3396642,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":148048,"kind":"person","name":"Christenson Johan","position":1,"cik":"0001488771","reported_name":"Christenson Johan","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-10-07T19:33:59.000Z","date":"2019-10-07","kind":"purchase","acquired":true,"shares":266667,"price":15,"value":4000005.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These Shares and Preferred Stock are held directly by HealthCap VII, L.P. (\"HCLP\"). HealthCap VII GP SA (\"HCSA\") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB.  The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These Shares and Preferred Stock are held directly by HealthCap VII, L.P. (\"HCLP\"). HealthCap VII GP SA (\"HCSA\") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB.  The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein."}],"balance_after":2366104,"source":{"system":"sec-edgar","filing":"0001140361-19-018087","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1488771/000114036119018087/form4.xml","form_type":"4"}},{"id":3396641,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":148048,"kind":"person","name":"Christenson Johan","position":1,"cik":"0001488771","reported_name":"Christenson Johan","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-10-07T19:33:59.000Z","date":"2019-10-07","kind":"exercise","acquired":true,"shares":427496,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock (\"Shares\"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These Shares and Preferred Stock are held directly by HealthCap VII, L.P. (\"HCLP\"). HealthCap VII GP SA (\"HCSA\") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB.  The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These Shares and Preferred Stock are held directly by HealthCap VII, L.P. (\"HCLP\"). HealthCap VII GP SA (\"HCSA\") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB.  The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein."}],"balance_after":2099437,"source":{"system":"sec-edgar","filing":"0001140361-19-018087","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1488771/000114036119018087/form4.xml","form_type":"4"}},{"id":3396640,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":148048,"kind":"person","name":"Christenson Johan","position":1,"cik":"0001488771","reported_name":"Christenson Johan","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-10-07T19:33:59.000Z","date":"2019-10-07","kind":"exercise","acquired":true,"shares":1661382,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock (\"Shares\"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering.  The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These Shares and Preferred Stock are held directly by HealthCap VII, L.P. (\"HCLP\"). HealthCap VII GP SA (\"HCSA\") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB.  The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These Shares and Preferred Stock are held directly by HealthCap VII, L.P. (\"HCLP\"). HealthCap VII GP SA (\"HCSA\") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB.  The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein."}],"balance_after":1671941,"source":{"system":"sec-edgar","filing":"0001140361-19-018087","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488771/000114036119018087/form4.xml","form_type":"4"}}]}